Model establishment, Characterization and Evaluation of treatment effect of chemotherapy in treatment-resistant breast cancer xenograft

Godkjenningsdato
Godkjent fra
Godkjent til
Currently, there are two main classes of cytotoxic drugs used in clinical management of breast cancer patients. Taxanes (e.g. paclitaxel) and doxorubicin. In clinical practice for aggressive disease, most of the patients will recieve a combination of these two drugs, following each other.

During treatment of breast cancer in patient after a period of time primary tumor or metastasis can become resistant to treatment. The is one of the main challenges in modern oncology. The possible mechanism are poorly understood or even unknown in some cases. To investigate such treatment resistance, and interfere with the development using targeting of growth pathways, we propose to use xenograft models for breast cancer, where human tumors are available and implanted into the mammary fat pad of immunodeficient mice, and show identical features as the tumor tissue they are derived from, developed in our facility and by collaborators.
In order to do so we will need to serially passage the tumors in living animals, take out tissue for analysis and study the effect of other drugs on growth and other biological factors of the tumor models.

In these experiments, we apply for the use of 196 mice. The experiments are based on a number of previous research experiments in the laboratory, in ours, collaboration partners, and published data. The studies are divided in two for each of the treatment combination, enabling the option of not carrying out the second part of the experiment if the obtained result from the first not justifies a continuation of the studies, to reduce the number of animals used to a minimum. Samples for molecular research will be taken to optimize the output and learning value from the studies.